Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2023 Earnings Call Transcript

Page 6 of 6

Lishan Aklog: So thank you all for joining us today and for the great questions. I do actually have one additional comment that came from one of our investors that they asked the question of EsoCure because PAVmed released – had a press release recently that indicated that it was reviving some projects, which included EsoCure. And I just wanted to confirm and remind folks that EsoCure, which is an esophageal ablation technology that fits very nicely within the portfolio of products that’s used to treat the later stage pre-cancers we discover with EsoGuard, that Lucid continues to have a fully exclusive license to commercialize that. So although it’s being revived at the PAVmed level, and PAVmed is seeking financing to complete its development, including some non-dilutive financing, Lucid remains the – will be the commercial entity that commercializes it, if and when we’re able to get that across the finish line.

So with that, as always, we look forward to keeping you abreast of our progress via news releases and periodic calls such as this one. And the best way to keep up with our news, updates and events is to sign up for e-mail alerts on the Lucid Investor Relations website and to follow us on Twitter, LinkedIn and on our website. So thank you, everybody, and have a great day.

Operator: Thank you, presenters. And ladies and gentlemen, this concludes today’s conference call. Thank you for participating. You may now disconnect.

Follow Lucid Diagnostics Inc.

Page 6 of 6